Swipe om te navigeren naar een ander artikel
About 30 years ago, the first Dutch unifactorial guidelines on hypertension and hypercholesterolaemia were developed. These guidelines have been revised several times, often after publication of landmark studies on new generations of drugs. In 1978, cut-off points for pharmacological treatment of hypertension were based on diastolic blood pressure values ≥115 mmHg, and in 2000 they were lowered to >100 mmHg. From 1997 onwards, cut-off points for systolic blood pressure values >180 mmHg were introduced, which became leading. In 1987, cut-offs for hypercholesterolaemia of ≥8 mmol/l were set and from 2006 pharmacological treatment was based on a total/HDL cholesterol ratio >8. Around 2000, treatment decisions for hypertension and/or hypercholesterolaemia were no longer based on high levels of individual risk factors, but on a multifactorial approach based on total risk of cardiovascular diseases (CVD), determined by a risk function. In the 2006 multidisciplinary guideline on cardiovascular risk management, the Framingham risk tables were replaced by European SCORE risk charts. A cut-off point of 10% CVD mortality was set in the Netherlands. In 2011, this cut-off point changed to 20% fatal plus nonfatal CVD risk. Nowadays, ‘the lower the risk factors, the lower the absolute risk’ is the leading paradigm in CVD prevention.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Interim advice on hypertension. Health Council, The Hague, 1978/18.
Advice on hypertension. Health Council, The Hague, 1983/2.
Cholesterol. Health Council, The Hague, 1990/1.
Consensus diagnostics and treatment of hypertension. Hart Bulletin 1990;21:142–210.
Cholesterol consensus. Hart Bulletin supplement 1987;1:3–64.
van Binsbergen JJ, Grundmeyer HGLM, van den Hoogen JPH, et al. NHG-Guideline on hypertension. Huisarts Wet. 1991;34:389–95.
van Binsbergen JJ, Brouwer A, van Drenth BB, et al. NHG-Guideline on cholesterol. Hart Bulletin supplement. 1992;23:27–35.
Multidisciplinary guideline on cardiovascular risk management. CBO/NHG, Utrecht 2006.
Smulders YM, Burgers JS, Scheltens T, et al. Clinical practice guideline for cardiovascular risk management in the Netherlands. Neth J Med. 2008;66:169–74. PubMed
NHG-Guideline on cardiovascular risk management (M84). nhg.artsennet.nl. 2006.
Walma EP, Grundmeyer HGLM, Thomas S, et al. NHG-Guideline on hypertension M17 (first revision). Huisarts Wet. 1997;40:598–617.
Walma EP, Grundmeijer HGLM, Thomas S, et al. NHG-Guideline on hypertension (second revision 1999). In: Geijer RMM, Burgers JS, van der Laan JR, Wiersma T, Rosmalen DFH, Thomas S, editors. NHG-Guidelines for general practitioners part I. Maarssen: Elsevier/Bunge; 1999.
Revision of guideline high blood pressure. CBO/NHF, Utrecht/The Hague, 2000.
Walma EP, Thomas S, Prins A, et al. NHG-Guideline on hypertension (M17) (third revision). Huisarts Wet. 2003;46:435–49.
Revision consensus cholesterol. Hart Bulletin supplement 1992;23:2–26.
Consensus cholesterol, second revision. Hart Bulletin 1998;29:112–131.
Thomas S, van der Weijden T, van Drenth BB, et al. NHG-Guideline on cholesterol M20 (first revision). Huisarts Wet. 1999;42:406–17.
Cholesterol lowering therapy. Health Council, The Hague, 2000/17.
Multidisciplinary guideline on cardiovascular risk management (revision). NHG, Utrecht, 2011.
Hypertension detection and follow-up program cooperative group. Five-year findings of the hypertension detection and follow-up program. JAMA 1979;242:2562–77.
Report by the management committee. The Australian therapeutic trial in mild hypertension. Lancet 1980;i:1261–7.
Treating mild hypertension:agreement from the large trials. Report of the British Hypertension Society working party. BMJ 1989;298:694–8.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981–97.
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351–64.
Jukema JW, Bruschke A, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528–40. PubMedCrossRef
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.
Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300–31. PubMed
Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of european and other societies on coronary prevention. Eur Heart J. 1998;19:1434–503. CrossRef
Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58. PubMedCrossRef
De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2003;10:S1–10. PubMedCrossRef
Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1–113. PubMedCrossRef
- Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach
I. van Dis
J. M. Geleijnse
W. M. M. Verschuren
- Bohn Stafleu van Loghum